CN105579464B - 能够再活化p53突变体的肽 - Google Patents

能够再活化p53突变体的肽 Download PDF

Info

Publication number
CN105579464B
CN105579464B CN201480053550.8A CN201480053550A CN105579464B CN 105579464 B CN105579464 B CN 105579464B CN 201480053550 A CN201480053550 A CN 201480053550A CN 105579464 B CN105579464 B CN 105579464B
Authority
CN
China
Prior art keywords
peptide
protein
mutant
cells
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480053550.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN105579464A (zh
Inventor
M.奥伦
V.罗特
P.塔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of CN105579464A publication Critical patent/CN105579464A/zh
Application granted granted Critical
Publication of CN105579464B publication Critical patent/CN105579464B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201480053550.8A 2013-08-07 2014-08-07 能够再活化p53突变体的肽 Expired - Fee Related CN105579464B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361862977P 2013-08-07 2013-08-07
US61/862977 2013-08-07
PCT/IB2014/063777 WO2015019318A1 (en) 2013-08-07 2014-08-07 Peptides capable of reactivating p53 mutants

Publications (2)

Publication Number Publication Date
CN105579464A CN105579464A (zh) 2016-05-11
CN105579464B true CN105579464B (zh) 2021-01-26

Family

ID=52460737

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480053550.8A Expired - Fee Related CN105579464B (zh) 2013-08-07 2014-08-07 能够再活化p53突变体的肽

Country Status (12)

Country Link
US (4) US9856289B2 (enExample)
EP (1) EP3030571B1 (enExample)
JP (2) JP6554099B2 (enExample)
CN (1) CN105579464B (enExample)
AU (2) AU2016200713B2 (enExample)
BR (1) BR112016002721A2 (enExample)
CA (1) CA2920147C (enExample)
ES (1) ES2795982T3 (enExample)
HU (1) HUE049292T2 (enExample)
IL (2) IL243944B (enExample)
RU (2) RU2693487C2 (enExample)
WO (1) WO2015019318A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015019318A1 (en) 2013-08-07 2015-02-12 Yeda Research And Development Co. Ltd. Peptides capable of reactivating p53 mutants
CN105112377B (zh) * 2015-09-25 2018-10-30 福州迈新生物技术开发有限公司 一株分泌抗p53单克隆抗体的杂交瘤细胞株及其应用
RU2762089C2 (ru) * 2016-02-04 2021-12-15 Иеда Рисеч Энд Девелопмент Ко. Лтд. ПЕПТИДЫ И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ, НАРУШЕНИЙ ИЛИ СОСТОЯНИЙ, АССОЦИИРОВАННЫХ С МУТАНТНЫМ р53
US20220251159A1 (en) * 2016-02-04 2022-08-11 Yeda Research And Development Co., Ltd Peptides and use of same in the treatment of diseases, disroders or conditions associated with a mutant p53
MX421596B (es) * 2017-09-29 2025-03-14 Us Health Receptores de celulas t que reconocen p53 mutado
CA3084369A1 (en) 2017-12-07 2019-06-13 Reven, Llc Compositions and methods for the treatment of metabolic conditions
WO2019116376A1 (en) * 2017-12-17 2019-06-20 Yeda Research And Development Co. Ltd. Cop9 signalosome (csn) complex modulators and uses thereof
WO2019134070A1 (en) * 2018-01-02 2019-07-11 Rui Jin Hospital, Shanghai Jiao Tong University School Of Medicine Panda as novel therapeutic
WO2019134650A1 (en) * 2018-01-02 2019-07-11 Rui Jin Hospital, Shanghai Jiao Tong University School Of Medicine Mp53 rescue compounds and methods of treating a p53 disorder
JP2022536708A (ja) * 2019-06-12 2022-08-18 リーベン アイピー ホールディングカンパニー リミテッド ライアビリティ カンパニー がん患者の予後を改善する方法および組成物
JP7402026B2 (ja) 2019-11-27 2023-12-20 株式会社小松製作所 作業機械の制御システム、作業機械、作業機械の制御方法
US20230127559A1 (en) 2020-03-16 2023-04-27 Yeda Research And Development Co. Ltd. Peptide analogs and use of same in treating diseases, disorders or conditions associated with mutant p53 protein
CN111574591B (zh) * 2020-04-29 2021-09-21 西安交通大学医学院第一附属医院 一种多肽及其合成方法
CN113750246B (zh) * 2020-06-04 2023-12-05 华南理工大学 ZIF-8纳米材料在降解广谱突变p53蛋白中的应用
CN111686127B (zh) * 2020-06-04 2022-02-15 华南理工大学 锌铁纳米材料在降解突变p53蛋白中的应用
WO2021262483A1 (en) * 2020-06-24 2021-12-30 Pmv Pharmaceuticals, Inc. METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION
JP2024501840A (ja) * 2020-12-21 2024-01-16 アラウヌス バイオサイエンシズ， インコーポレイテッド ペプチダーゼ切断可能基質およびその同定方法ならびにその使用方法
CN112921032A (zh) * 2020-12-29 2021-06-08 苏州中科先进技术研究院有限公司 一种引物对、探针、试剂盒及其使用方法
CN115466786A (zh) * 2021-06-11 2022-12-13 上海交通大学医学院附属瑞金医院 一种筛选适合用p53复活药物治疗p53异常相关疾病病人的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025434A1 (en) * 1995-02-16 1996-08-22 The Wistar Institute PEPTIDES AND PEPTIDOMIMETICS WITH STRUCTURAL SIMILARITY TO HUMAN p53 THAT ACTIVATE p53 FUNCTION
EP0989136A1 (en) * 1997-05-15 2000-03-29 Kyowa Hakko Kogyo Co., Ltd. Peptides having cyclic structures and exerting p53 protein activty-restoring effect on p53 protein mutants

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5294605A (en) 1990-07-19 1994-03-15 The Scripps Research Institute Amphiphilic peptide compositions and analogues thereof
US5614393A (en) 1991-10-10 1997-03-25 Rhone-Poulenc Agrochimie Production of γ-linolenic acid by a Δ6-desaturase
US5969120A (en) * 1993-09-03 1999-10-19 Research Development Foundation Mutants of the RB and P53 genes
US6184205B1 (en) 1994-07-22 2001-02-06 University Of North Carolina At Chapel Hill GRB2 SH3 binding peptides and methods of isolating and using same
US5877282A (en) 1996-09-20 1999-03-02 Bristol-Myers Squibb Company Peptide inhibitors of nuclear protein translocation having nuclear localization sequences and methods of use thereof
US20030224379A1 (en) * 2000-01-21 2003-12-04 Tang Y. Tom Novel nucleic acids and polypeptides
WO2002072600A2 (en) 2001-01-26 2002-09-19 Inhibitex, Inc. Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections
EP1472276A4 (en) * 2001-02-28 2007-05-09 Keith M Skubitz PEPTIDES OF SMALL SIZE CAPACITY TO MODULATE THE FUNCTION OF THE MEMBERS OF THE FAMILY OF CD66 (CEACAM)
EP1515985B1 (en) * 2002-01-23 2013-01-02 Mohammed Raafat El-Gewely Methods of screening molecular libraries for active molecules that restore the function of mutant p53
US7361747B2 (en) * 2003-05-22 2008-04-22 The University Of Hong Kong Isolation and characterization of the precursor virus of human SARS virus: SARS-associated corona virus-like virus
CA2600370A1 (en) * 2005-03-14 2006-09-14 Board Of Regents Of The University Of Texas System Bioactive fus1 peptides and nanoparticle-polypeptide complexes
US8877201B2 (en) * 2007-10-25 2014-11-04 Wake Forest University Health Sciences Bordetella outer-membrane protein antigens and methods of making and using the same
WO2009112075A1 (en) * 2008-03-13 2009-09-17 Universita' Degli Studi Di Trieste Peptides and aptamers thereof as specific modulators of mutant p53 function
US8287845B2 (en) * 2008-12-18 2012-10-16 E I Du Pont De Nemours And Company Hair-binding peptides
WO2013036208A1 (en) * 2011-09-09 2013-03-14 Agency For Science, Technology And Research P53 activating peptides
EP2771349B1 (en) * 2011-09-16 2020-02-26 Iogenetics, LLC. Bioinformatic processes for determination of peptide binding
US9657064B2 (en) * 2012-09-13 2017-05-23 Les Hopitaux Universitaires De Geneve Cell penetrating peptides
WO2015019318A1 (en) 2013-08-07 2015-02-12 Yeda Research And Development Co. Ltd. Peptides capable of reactivating p53 mutants
RU2762089C2 (ru) 2016-02-04 2021-12-15 Иеда Рисеч Энд Девелопмент Ко. Лтд. ПЕПТИДЫ И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ, НАРУШЕНИЙ ИЛИ СОСТОЯНИЙ, АССОЦИИРОВАННЫХ С МУТАНТНЫМ р53

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996025434A1 (en) * 1995-02-16 1996-08-22 The Wistar Institute PEPTIDES AND PEPTIDOMIMETICS WITH STRUCTURAL SIMILARITY TO HUMAN p53 THAT ACTIVATE p53 FUNCTION
EP0989136A1 (en) * 1997-05-15 2000-03-29 Kyowa Hakko Kogyo Co., Ltd. Peptides having cyclic structures and exerting p53 protein activty-restoring effect on p53 protein mutants

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Small peptides activate the latent sequencespecific DNA binding function of p53;Ted R. Hupp et al.,;《Cell》;19951020;第83卷;237-245 *

Also Published As

Publication number Publication date
IL243944B (en) 2019-08-29
EP3030571A4 (en) 2017-05-10
HK1219742A1 (en) 2017-04-13
US20200095282A1 (en) 2020-03-26
RU2019119609A3 (enExample) 2019-12-30
BR112016002721A2 (pt) 2018-07-10
JP2019214573A (ja) 2019-12-19
JP2016527891A (ja) 2016-09-15
IL243944A0 (en) 2016-04-21
HUE049292T2 (hu) 2020-09-28
US9856289B2 (en) 2018-01-02
CA2920147A1 (en) 2015-02-12
CA2920147C (en) 2022-09-20
US20190315804A1 (en) 2019-10-17
RU2721423C2 (ru) 2020-05-19
CN105579464A (zh) 2016-05-11
US20160215019A1 (en) 2016-07-28
AU2016200713A1 (en) 2016-05-19
RU2019119609A (ru) 2019-08-07
US11028127B2 (en) 2021-06-08
JP6554099B2 (ja) 2019-07-31
IL268355A (en) 2019-09-26
US10336789B2 (en) 2019-07-02
EP3030571A1 (en) 2016-06-15
EP3030571B1 (en) 2020-03-18
RU2693487C2 (ru) 2019-07-03
RU2016106583A3 (enExample) 2018-03-29
AU2016200713B2 (en) 2017-02-02
RU2016106583A (ru) 2017-08-30
AU2017202806B2 (en) 2018-04-05
US10550152B2 (en) 2020-02-04
ES2795982T3 (es) 2020-11-25
US20180057533A1 (en) 2018-03-01
WO2015019318A1 (en) 2015-02-12
AU2017202806A1 (en) 2017-05-18

Similar Documents

Publication Publication Date Title
CN105579464B (zh) 能够再活化p53突变体的肽
JP2024161501A (ja) ミスフォールドタンパク質の分解のための組成物及び方法
CN103180340A (zh) 细胞内免疫
JP2022112518A (ja) 変異型ｐ５３と関連している疾患、障害または病状の処置におけるペプチドおよびその使用
JP2023512562A (ja) 人工シナプス
Bartl et al. Inhibiting cellular uptake of mutant huntingtin using a monoclonal antibody: Implications for the treatment of Huntington's disease
US8414887B2 (en) Methods for suppressing Toll-like Receptor 4 (TLR4) function using TLR14 antagonists
US9683025B2 (en) Methods and compositions for treating cancer and inflammatory diseases
HK1219742B (en) Peptides capable of reactivating p53 mutants
CA2919855A1 (en) Peptides capable of reactivating p53 mutants
KR20080034995A (ko) 혈관 투과성을 저해하는 방법 및 조성물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20210126